An observational study in Rectal Neoplasms and Rectal Cancer, sponsored by Maria Sklodowska-Curie National Research Institute of Oncology. Recruiting at 7 sites in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-09-19.
Sponsored by Maria Sklodowska-Curie National Research Institute of Oncology · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies in Rectal Neoplasms with a site in Poland — 4 open to participants now, 8 under way, 3 of them phase 3. Rectal Neoplasms · Poland.
Among the 31 studies in Rectal Neoplasms with a site in Poland, this one is one of 2 that started in 2017, is one of 3 observational ones, and was the 19th registered.
2,404 studies on the registry are indexed under Rectal Neoplasms; 588 are open to participants now.
Browse Rectal Neoplasms studies →4 of the 31 studies in Rectal Neoplasms with a site in Poland are open now. Recruiting first, the newest first:
Medical University of Gdansk · Sites in Poland, France
Ages 18+
Merck Sharp & Dohme LLC · Sites in Poland, United States, Argentina and 26 more countries
Ages 18+
Jagiellonian University · Sites in Poland
Ages 18+
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 404 Rectal Neoplasms studies recruiting now, 209 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 11 · Phase 4 1
First in 1993; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 215 is above the median of 161 across 499 observational studies indexed under Rectal Neoplasms.
Median enrollment 260 across the 27 interventional studies, 300 across the 3 observational. Of the 15 that completed or were terminated, 2 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 31 have an industry lead sponsor. The 10 most frequent:
Maria Sklodowska-Curie National Research Institute of Oncology is the lead sponsor of 64 studies on the registry; 13 are open to participants now.
Maria Sklodowska-Curie National Research Institute of Oncology has 6 studies filed under Rectal Neoplasms — fewer than ten, so there is no comparison to draw.
1 of the studies in Rectal Neoplasms with a site in Poland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05462717Revolution Medicines, Inc.Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors | 2027-03-31 |
Add it to your calendar (.ics) → With an account.
Among the 31 studies in Rectal Neoplasms with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Watch-and-wait strategy in rectal cancer is gaining momentum. There is a large variability in reporting the proportion of patients achieving clinical complete response (cCR) after routinely delivered preoperative radio(chemo)therapy, likely because of patients' selection. This proportion in population-based level is poorly defined. In addition, predictive factors for cCR are also poorly defined. It is known that cCR response is observed often in small tumours. However, cCR proportion in large cancers has not been sufficiently evaluated. For example, even though pathological complete response (pCR) does occur in large fixed cancer, it is unknown whether cCR does also occur because persistent fibrous stroma may mimic residual cancer in all of such cases.
This is a prospective observational population-based cohort study on low rectal cancer to answer the question of how often clinical or near-clinical tumour response occur after routinely delivered preoperative radiotherapy in relation to the pre-treatment tumour characteristics. The additional question was how often pCR occur in relation to the pre-treatment tumour characteristics in the patients managed by total mesorectal excision because of persistent tumour after radiotherapy. The additional aim was the implementation of watch-and-wait strategy or full-thickness local excision (as an option instead of total mesorectal excision in the patients with sustained near-cCR) within a frame of a prospective study. In the patients managed by organ preservation, the secondary outcome measures were: i) local regrowth rate, ii) effectiveness of salvage surgery, iii) disease-free survival at 3 years and overall survival at 5 years, iv) anorectal function.
140 patients with "resectable" cancer and 75 patients with threatened mesorectal fascia as assessed on multidisciplinary tumor board.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Radiation: Preoperative Radio(Chemo)Therapy
Radiation: Preoperative Radio(Chemo)Therapy
Preoperative radiotherapy +/- chemotherapy, then surgery (total mesorectal excision) or watch-and-wait
Percentages of cCR and near-cCR in the patients with "resectable" cancer
Time frame: 11 weeks from the start of radiotherapy
Percentages of cCR and near-cCR in the patients with threatened mesorectal fascia.
Time frame: 11 weeks from the start of radiotherapy
Percentages of cCR and near-cCR in relation to the selected tumour characteristics.
The selected tumour characteristics: TN categories, tumour length, degree of circumferential involvement, tumour mobility on digital rectal examination (mobile, tethered, fixed) and status of mesorectal fascia (threatened or not).
Time frame: 11 weeks from the start of radiotherapy
Percentages of pCR in the patients after total mesorectal excision performed because of tumour persistence.
Time frame: 12 weeks from the start of radiotherapy
Local regrowth rate
Time frame: 5 years
Disease-free survival
Time frame: 3 years
Overall survival
Time frame: 5 years
Anorectal function assessed by low anterior resection syndrome (LARS) score
The questionnaire will be completed by patients. It includes 5 items related to anorectal function. The range of the score (0-42) is divided into 0 to 20 (no LARS), 21 to 29 (minor LARS) and 30 to 42 (major LARS).
Time frame: 3 years
Plan to share: Undecided
No publications or documents are linked to this record.
Started Sep 2017 (actual). Primary completion is estimated for Jan 2021, 39 months after the start.
Of 214 non-industry observational studies under Rectal Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 118. This study's planned 39 months is below that.
Counting every sponsor, half of 229 studies reached it within 45 months; a quarter within 24 and three quarters within 116.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Maria Sklodowska-Curie National Research Institute of Oncology